Agatolimod ((ODN 2006; PF-3512676; CpG 7909)) is a TLR9 agonist and immunomodulator with an EC 50 of 180 nM against human TLR9 . Agatolimod activates and upregulates the expression of both TLR9 and TLR6 , and mediates downstream signaling pathways via IRAK4 , IRF5, IRF7 . Agatolimod induces Th1-type innate and adaptive immune responses, activates various immune cells and promotes antigen presentation, regulates antibody levels and immune cell infiltration, upregulates the secretion of multiple cytokines, induces apoptosis and cell cycle arrest, enhances cytotoxicity, and clears intracellular Salmonella. Agatolimod is applicable to research on COVID-19 , breast cancer , lung adenocarcinoma, HPV-related tumors, melanoma, and salmonellosis.
Products | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Infection | Products > Disease Areas > Cervical Cancer | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Melanoma | Products > Disease Areas > Bacterial Infection | Products > Disease Areas > HPV-Positive Cervical Cancer | Products > Disease Areas > Cancer | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > Anti-infection | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Infection | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Toll-like Receptor (TLR) | Products > Signaling Pathways > Bacterial | Products > Signaling Pathways > NO Synthase | Products > Signaling Pathways > Apoptosis
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.
日本语
한국어
Français
Deutsch
España
Türkiye